Management Team
Carsten Buhl was appointed Chief Executive Officer of BioPorto effective September 1, 2025. He brings over 25 years of leadership experience in the MedTech and Life Science industries. Prior to joining BioPorto, Carsten served as President of the Americas at WSAudiology, where he was a member of the executive management team. His career also includes senior leadership roles at Natus Medical Inc., Ambu, and GN Store Nord, among others. Carsten is recognized for his deep expertise in general management and his global perspective, having led and transformed teams across multiple continents. He has a proven track record in scaling businesses, executing go-to-market strategies, launching innovative products, and driving operational excellence. He holds a Master of Law from Copenhagen University and an Executive MBA.
Klaus Juhl Wulff was appointed Executive Vice President & Chief Financial Officer on April 1, 2026. He is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He recently joined BioPorto from AquaPorin A/S, where he served as CFO from 2022. Prior to this, Klaus Juhl Wulff has acted as CFO across various companies. Klaus Juhl Wulff holds a Master of Science in Finance and Administration from Aarhus University supplemented with various leadership education.
Gry Husby Larsen was appointed Executive Vice President and Chief Legal Officer in April 2024. Gry has been with BioPorto since 2011, initially as the General Counsel, where she led the company’s legal and HR activities, including compliance, fundraising, intellectual property rights, contracts, Board support, HR, and ESG. From 2019 – 2024, Gry served as an external General Counsel for BioPorto while also holding part-time General Counsel positions at FluoGuide A/S, Algiecel A/S, and Unibio A/S, as well as conducting consultancy work through HUSBY ApS. Before joining BioPorto, Gry was an Attorney-at-law at Knop & Co. Law Firm. Her extensive legal and commercial experience in the biotech industry is a significant asset in the growth and development of BioPorto. Gry holds a Master of Law degree from the University of Copenhagen.
Other directorships: BioPorto Diagnostics A/S (Chair), HUSBY ApS (CEO)
Jennifer Zonderman first joined the US team in May 2019 and is now Senior Vice President Global Marketing & Commercialization. Jennifer excels at leading sales organizations through change such as growth, new markets, product launches and team integrations. Focusing on process and system improvements and developing methods and teams to consistently achieve revenue goals is the key to her success. Jennifer’s sales career has spanned both medical and high tech. She has a Master’s Certificate from Wayne State and a Bachelor of Science from Alma College.
Dr. Jakob Felding joined BioPorto April 2026 as Chief Science Officer, CSO and leads the global clinical and technical development teams incl. Clinical and Regulatory Affairs – a group of highly qualified and motivated professionals passionate about providing superior products to improve patients’ lives. Jakob recently joined BioPorto from the Union TX and has a strong scientific background with more than 25 years of extensive relevant experience in life science, incl. 15 years from Leo Pharma A/S where he held multiple manager positions. Jakob holds a Ph.D. in medicinal chemistry from the Royal Danish School of Pharmacy, University of Copenhagen.
Asger Dahlgaard first joined BioPorto as Vice President of Quality Assurance and Regulatory Affairs in October 2021. With more than 20 years in the medical industry, Asger is now focused on ensuring BioPorto’s quality management system is flawless. Asger provides a proven track record in the management of global quality organizations, strategic thinking, and execution. While at Agilent Technologies, Asger managed a team of 45 to provide ongoing quality support including management reviews, and audits (FDA, notifying bodies, internal and vendor). His experience also includes managing and supporting major IT implementations and a new IVD-R system for Complaints, Vigilance, NCR, and Post Market Surveillance. Asger holds a Bachelor of Science in Engineering from the DTU-Technical University of Denmark.
Dr. Prasad Devarajan
Senior Medical Director
With over 40 years of medical experience, Dr. Prasad Devarajan, MD, FAAP, FASN, joined the BioPorto team as Senior Medical Director in July 2022. He is a world-renown pediatric nephrologist at Cincinnati Children’s Hospital Medical Center in Ohio, where he is the Director of the Nephrology and Hypertension Division, Medical Director of the Stone Center, and Professor at the UC Department of Pediatrics. In addition, Dr. Devarajan is on the editorial and review boards of more than 20 journals and multiple US National Institutes of Health (NIH) study sections. He has authored more than 320 peer-reviewed journal articles, and his work has been continuously funded by NIH and several other foundations for over 30 years. He graduated from Lokmanya Tilak Municipal Medical College medical school.